|
PRESS RELEASE - 11/26/2008
Intralytix wins Phase III Army grant for E. Coli
technology
Baltimore, Maryland U.S.A. – November 26, 2009 - -
Intralytix, Inc., announced today that it has been named a
recipient of a 2009 Army Commercialization Pilot Program (CPP)
grant to support the development of a phage-based technology for
eliminating or significantly reducing contamination of fruits,
vegetables and red meat by E. coli 0157:H7. The grant is
an outgrowth of prior Phase I and Phase II Small Business
Innovation Research (SBIR) grants from the Army supporting
Intralytix’s food additive product, ECP 100. ECP 100 is a
bacteriophage cocktail developed by Intralytix and tested
effective against over 100 strains of E. coli 0157:H7.
The product would be sprayed onto red meats, fruits and
vegetables to substantially reduce or completely eliminate
contamination by E. coli 0157:H7.
Under the Phase III grant, the Army will provide the company
with funding to support the transition ECP 100 into the
commercial marketplace, including business and transition plan
development, potential investment needs planning and
justification, and facilitation of meetings with potential
private/or government customers.
“We are pleased that the Army has recognized the importance
of our product and technology in ensuring the future safety of
the American food supply” stated John D. Vazzana, Intralytix’s
CEO. He noted that “the Center for Disease Control (CDC)
estimates that over 76 million people get sick, 300,000 are
hospitalized, and 5,000 Americans die from food-borne illness
annually.” “E-coli 0157:H7 is one of the 7 food-borne
organisms causing these problems,” he added.
ECP 100 is the second phage-based food safety product
developed by Intralytix. The company had already received FDA
and EPA approval of its first food safety product, LMP 102, a
product effective against Listeria monocytogenes.
Commercial sales of LMP 102 have recently commenced.
Intralytix, Inc. is a biotechnology company focused on
improving human health through the development and
commercialization of innovative products for food safety and
human therapeutics using its core bacteriophage technology
platform.
For more information, contact Dr. Alexander Sulakvelidze at 410-625-2533,
or at asulakvelidze@intralytix.com.
Intralytix, Inc.
701 East Pratt Street
Baltimore, MD 21202
www.intralytix.com
|
